Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2013-05-30

Last Posted Date: 2015-10-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01865292

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec
Drug: placebo
Drug: insulin degludec/insulin aspart 50

First Posted Date: 2013-05-30

Last Posted Date: 2016-01-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01865331

Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec

First Posted Date: 2013-05-30

Last Posted Date: 2015-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01865318

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart 40
Drug: insulin degludec/insulin aspart 30
Drug: biphasic insulin aspart 30
Drug: insulin degludec/insulin aspart 50
Drug: insulin degludec
Drug: insulin aspart

First Posted Date: 2013-05-30

Last Posted Date: 2015-10-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 59

Registration Number: NCT01865305

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency

Interventions: Drug: catridecacog

First Posted Date: 2013-05-24

Last Posted Date: 2019-07-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01862367

Locations: 🇬🇧
Novo Nordisk Investigational Site, Aberdeen, United Kingdom

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart
Drug: basal insulin

First Posted Date: 2013-05-09

Last Posted Date: 2019-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 323

Registration Number: NCT01850615

Locations: 🇸🇮
Novo Nordisk Investigational Site, Novo mesto, Slovenia

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Degludec
Drug: Insulin Glargine

First Posted Date: 2013-05-08

Last Posted Date: 2017-04-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 833

Registration Number: NCT01849289

Locations: 🇺🇦
Novo Nordisk Investigational Site, Vinnitsa, Ukraine

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Congenital FXIII Deficiency
Congenital Bleeding Disorder
Healthy

Interventions: Drug: catridecacog
Drug: placebo

First Posted Date: 2013-05-07

Last Posted Date: 2013-11-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01848002

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency
Healthy

Interventions: Drug: placebo
Drug: catridecacog

First Posted Date: 2013-05-07

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT01847989

Locations: 🇬🇧
Novo Nordisk Investigational Site, Berkshire, United Kingdom

An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2013-05-03

Last Posted Date: 2015-09-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01846312

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy